FX-322 in Sensorineural Hearing Loss

NCT03616223 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Sensorineural Hearing Loss

Interventions

DRUG: FX-322
DRUG: Placebo

Sponsor

Frequency Therapeutics